Sign in
PCVX Stock Price, Chart, Stats & News
Vaxcyte, Inc.
Save
7.84B
Market cap
–
Current P/E
–
Forward P/E
PCVX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -25.17% |
ROE | -25.88% |
D/E | 0.09x |
Interest coverage ratio | – |
PCVX valuation
P/E | – |
P/S | – |
P/B | 2.69x |
P/CF | -11.04x |
P/FCF | -11.43x |
P/OCF | -11.04x |
PEG | 0.68x |
EV multiple | -9.72x |
About
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia.
Similar securities
Based on sector and market capitalization
Report issue